Invivoscribe, Inc. and its wholly owned subsidiary LabPMM, LLC are collecting peripheral blood specimens from patients with suspected SARS-CoV-2 viral infections. These donors will be from a population of patients who are already providing nasal pharyngeal (NP) swab samples in universal transport media (UTM) for COVID-19 testing at LabPMM LLC. Specimens meeting this research protocol's inclusion criteria may be evaluated with various molecular techniques in order to identify nucleic acid sequences, antibodies, and/or antigens with the potential of being used to develop novel SARS-CoV-2 detection methods and COVID- 19 treatments and/or prevention methods (e.g. drug or vaccine development).

This research protocol describes the collection and analysis of peripheral blood samples to:

• Identify nucleic acid sequences that may be used aide in the development of SARSCoV- 2 detection methods.
• Identify antibodies that may be used aide in the development of SARS-CoV-2 detection methods.
• Identify antigens that may be used aide in the development of SARS-CoV-2 detection methods. -Identify nucleic acid sequences that may be used aide in the development of COVID- 19 treatments and/or vaccines.
• Identify antibodies that may be used aide in the development of COVID-19 treatments and/or vaccines.
• Identify antigens that may be used aide in the development of COVID-19 treatments and/or vaccines.

Inclusion Criteria:

• From patients suspected of SARS-CoV-2 viral infections.
• From patients who have had COVID-19 testing prescribed by their treating physicians.
• From patients whose COVID-19 test specimen was sent to LabPMM, LLC for testing

Exclusion Criteria:

• There are no exclusion criteria related to age, gender, race, ethnicity, geography, and/or other medical conditions.

This is an open study that will accept donations from any patients who both are being tested by LabPMM, LLC for COVID-19 and who sign the related ICF.